{"id":"covax-iiv4-covax-ppv23","safety":{"commonSideEffects":[{"rate":null,"effect":"Injection site pain or swelling"},{"rate":null,"effect":"Fever"},{"rate":null,"effect":"Fatigue"},{"rate":null,"effect":"Myalgia"},{"rate":null,"effect":"Headache"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"COVAX is an inactivated COVID-19 vaccine that stimulates adaptive immune responses against SARS-CoV-2. When co-administered with IIV4 (inactivated influenza vaccine, 4-valent) or PPV23 (pneumococcal polysaccharide vaccine, 23-valent), these formulations provide simultaneous protection against multiple respiratory pathogens through humoral and cellular immunity.","oneSentence":"COVAX+IIV4 and COVAX+PPV23 are combination vaccines that provide immunization against COVID-19 (COVAX component) alongside seasonal influenza (IIV4) or pneumococcal disease (PPV23).","_ai_confidence":"medium"},"_scrapedAt":"2026-03-28T00:29:23.942Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"COVID-19 prevention (COVAX component)"},{"name":"Seasonal influenza prevention (IIV4 component)"},{"name":"Pneumococcal disease prevention (PPV23 component)"}]},"trialDetails":[{"nctId":"NCT04790851","phase":"PHASE4","title":"Evaluation of Immunogenicity and Safety of Combined Immunization of COVID-19 Vaccine (Produced in Beijing) and PPV23 / IIV4","status":"COMPLETED","sponsor":"China National Biotec Group Company Limited","startDate":"2021-03-10","conditions":"Influenza, Human, Pneumonia, Pneumococcal, Covid19","enrollment":1133},{"nctId":"NCT05079152","phase":"PHASE4","title":"Evaluation of Immunogenicity and Safety of Combined Immunization of COVAX (Produced in Wuhan) and PPV23 / IIV4","status":"UNKNOWN","sponsor":"China National Biotec Group Company Limited","startDate":"2021-05-06","conditions":"Influenza, Human, Pneumonia, Pneumococcal, COVID-19 Pneumonia","enrollment":1404}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"marketed","status":"active","brandName":"COVAX+IIV4; COVAX+PPV23","genericName":"COVAX+IIV4; COVAX+PPV23","companyName":"China National Biotec Group Company Limited","companyId":"china-national-biotec-group-company-limited","modality":"Biologic","firstApprovalDate":"","aiSummary":"COVAX+IIV4 and COVAX+PPV23 are combination vaccines that provide immunization against COVID-19 (COVAX component) alongside seasonal influenza (IIV4) or pneumococcal disease (PPV23). Used for COVID-19 prevention (COVAX component), Seasonal influenza prevention (IIV4 component), Pneumococcal disease prevention (PPV23 component).","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}